CHRISTUS Mother Frances Hospital - Tyler Patients to Benefit from Innovative Fluorescence Imaging Technology
August 20, 2018
TYLER, TX – CHRISTUS Mother Frances Hospital - Tyler announced today that plastic and reconstructive and other surgeries may now benefit from an innovative imaging technology called SPY-PHI. The use of Stryker’s SPY-PHI may help surgeons to make decisions during open surgery based on the quality of blood flow in vessels and micro vessels that provide oxygen to organs. Most often called tissue perfusion or simply perfusion, adequate blood flow is critical to tissue health and the ability to visualize blood flow in real-time may assist surgeons in achieving lower rates of postoperative complications and improved surgical outcomes. CHRISTUS Mother Frances Hospital - Tyler is the first hospital in the region to implement this advancement in surgery.
Traditionally, surgeons relied solely on their clinical judgment to determine whether or not tissue was receiving adequate perfusion to remain viable or healthy. The ability to visualize perfusion intraoperatively may assist surgeons in many clinical decisions including whether to go direct-to-implant or how much tissue to remove during an operation. Today at CHRISTUS Mother Frances Hospital - Tyler, surgeons can use SPY-PHI to see beyond what the human eye can see which has the potential to enhance their clinical judgment and help them optimize patient outcomes.
SPY-PHI uses a near-infrared low powered laser light source to stimulate a fluorescent imaging agent that has been injected into the blood stream. The fluorescent agent binds to the proteins in blood and circulates through the body. When stimulated by near infrared light, the protein-bound agent emits a fluorescence signal which enables visualization of blood flowing through vessels and into tissue. The fluorescence is captured by a special camera, is processed and is displayed on a video monitor for the surgeon to review. Since the agent is bound to blood, where blood goes, it goes. If there is no fluorescence, it can mean that there is compromised blood flow. In situations of poor perfusion, surgeons can make certain decisions or take action while the patient is still in the operating room. Unlike traditional X-ray, which can be cumbersome to perform in surgery, SPY technology does not involve ionizing radiation and utilizes a fluorescence imaging agent with a short half-life thus allowing surgeons to repeat perfusion assessment numerous times throughout the procedure.
“Bringing this technology to CHRISTUS Trinity Mother Frances Health System and to our patients here is truly an amazing step for medicine in Northeast Texas,” said Fadi Nasrallah, M.D., MBA, Vice President of Medical Affairs and Chief Medical Officer of CHRISTUS Trinity Mother Frances Health System. “Additionally, it represents the very best of what we aim to do every day for our patients: joining compassion and expertise to benefit those who require treatment. It is a wonderful example of our vision to be a leader, a partner and an advocate in the creation of innovative health and wellness solutions that improve the lives of individuals and communities so that all may experience God's healing presence and love.”
The use of SPY technology is well documented in medical literature with approximately 260 clinical publications. Published literature is supportive that the use of SPY may result in improved surgical outcomes and reduced healthcare costs. SPY is cleared for use in a variety of different applications including coronary artery bypass graft surgery, plastic, reconstructive and micro-surgery, gastrointestinal surgery, organ transplant, cardiovascular and minimally invasive surgery. SPY Technology is available in different embodiments that meet the specific needs of surgeons performing a variety of open and minimally invasive surgical procedures.